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Abstract
The	immune	checkpoint	inhibitor	nivolumab	inhibits	the	programmed	death	1	receptor	
and	suppresses	the	immune	resistance	of	cancer	cells.	This	is	a	long-term	follow	up	of	a	
single-arm,	open-label,	multicenter,	phase	II	study	of	nivolumab	in	untreated	Japanese	
patients	with	 stage	 III/IV	or	 recurrent	melanoma.	 In	 addition,	 a	 post–hoc	 subgroup	
analysis	stratified	by	melanoma	types	was	performed.	Nivolumab	was	administered	in-
travenously	at	a	dose	of	3	mg/kg	every	2	weeks.	The	primary	endpoint	was	the	overall	
response	rate	(ORR),	and	secondary	endpoints	included	overall	survival	(OS),	progres-
sion-free	survival	(PFS),	best	overall	response,	the	disease	control	rate	and	change	in	
tumor	diameter.	Safety	was	assessed	by	recording	treatment-related	adverse	events	
(TRAE),	 including	select	 immune-related	adverse	events.	Of	 the	24	patients	 initially	
included	in	the	primary	phase	II	study,	10	survived	for	over	3	years	(41.7%).	The	ORR	
was	34.8%	(90%	confidence	interval	[CI]:	20.8,	51.9)	for	all	patients.	When	analyzing	
by	melanoma	type,	the	ORR	was	66.7%	(90%	CI:	34.7,	88.3)	for	superficial	spreading,	
33.3%	(90%	CI:	11.7,	65.3)	for	mucosal,	and	28.6%	(90%	CI:	10.0,	59.1)	for	acral	len-
tiginous	tumors.	The	median	OS	was	32.9	months,	the	3-year	OS	rate	was	43.5%,	and	
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1  | INTRODUC TION
In	 the	 past	 10	 years,	 the	 practice	 of	 medical	 oncology	 has	 been	
transformed	by	 the	development	of	 immune	checkpoint	 inhibitors	
for	anticancer	treatment.1	Immune	checkpoint	inhibitors	are	now	at	
the	 forefront	 of	 cancer	 immunotherapy	 research	 as	 they	 enhance	
the	body's	own	anticancer	activities	by	modulating	lymphocytes	to	
recognize	tumor	cells.
The	immune	checkpoint	inhibitor,	nivolumab,	is	a	human	mono-
clonal	antibody	that	 inhibits	the	checkpoint	receptor,	programmed	
death	1	 (PD-1).	 In	 a	 previous	 phase	 II	 clinical	 trial	 (hereinafter	 re-
ferred	to	as	the	primary	phase	II	study)	that	investigated	nivolumab	
therapy	in	stage	III/IV	or	recurrent	melanoma,	it	was	reported	that	
nivolumab	 was	 clinically	 beneficial.2	 The	 overall	 response	 rate	
(ORR)	was	34.8%,	and	 the	overall	 survival	 (OS)	 rate	at	18	months	
was	56.5%.	A	subgroup	analysis	also	 revealed	 that	nivolumab	was	
effective	and	safe	regardless	of	BRAF	genotype.	This	is	clinically	im-
portant	because	melanomas	with	the	BRAF	mutation	are	reported	
to	 be	more	 aggressive	 and	 resistant	 to	 chemotherapy.	 Therefore,	
nivolumab	is	a	clinically	beneficial	treatment	option	in	Japanese	pa-
tients	with	advanced	or	recurrent	melanoma.3-5
The	present	study	evaluated	the	long-term	follow-up	results	(3-year	
OS)	in	Japanese	patients	with	advanced	malignant	melanoma	from	the	
primary	phase	II	study.2	In	addition,	the	OS	of	patients	with	acral	lentig-
inous	or	mucosal	melanoma	types	were	also	compared	against	the	OS	
of	patients	with	superficial	spreading.	This	is	because	acral	lentiginous	
and	mucosal	melanoma	types	are	more	prevalent	in	Japanese	patients	
(40%	and	10%,	respectively)	when	compared	with	Caucasian	popula-
tions,	and,	therefore,	 it	would	be	of	value	to	evaluate	the	efficacy	of	
treatment	in	melanoma	types	that	are	specific	to	Japanese	patients.6,7
2  | MATERIAL S AND METHODS
2.1 | Study design
The	primary	study	was	a	single-arm,	open-label,	multicenter	phase	II	
study.2	Here,	we	report	the	long-term	(3-year	OS)	follow-up	results	
of	patients	from	the	primary	phase	II	study	and	the	analysis	of	OS	
by	melanoma	types	that	are	prevalent	 in	the	Japanese	population.	
The	primary	study	consisted	of	3	stages:	screening,	intervention	and	
post–treatment	 follow-up.	 Patients	were	 originally	 enrolled	 into	 a	
screening	stage	after	which	eligible	patients	were	enrolled	into	the	
intervention	stage.	Nivolumab	was	administered	intravenously	at	a	
dose	of	3	mg/kg	every	2	weeks	in	a	6-week	cycle	until	progressive	
disease	 (PD)	 or	 unacceptable	 adverse	 events	 (AE)	were	 observed.	
The	criteria	 for	 study	drug	discontinuation	 included	 the	 following:	
complete	 response	 (CR)	 based	 on	 Response	 Evaluation	 Criteria	 in	
Solid	Tumors	 (RECIST)	guidelines	unless	 the	patient	was	expected	
to	experience	recurrence,	PD	based	on	RECIST	guidelines	with	no	
further	 clinical	 benefit	 expected,	 clinical	 symptoms	 that	 indicated	
cancer	progression,	grade	≥2	 interstitial	 lung	disease,	grade	≥3	AE	
that	were	not	ruled	out	to	be	related	to	nivolumab,	or	grade	≥2	AE	
(eye	pain	and	visual	acuity	reduced)	that	could	not	be	ruled	out	to	
be	related	to	nivolumab.	Tumors	were	evaluated	at	the	end	of	each	
6-week	cycle	to	determine	whether	treatment	should	be	continued.	
The	follow-up	stage	started	when	treatment	was	discontinued	or	no	
new	cycle	was	started.
2.2 | Patients
This	study	 included	Japanese	patients	with	unresectable	stage	 III/
IV	 or	 recurrent	 malignant	 melanoma	 according	 to	 the	 Union	 for	
International	Cancer	Control-TNM	classification	(version	7).	Patients	
were	included	if	the	following	criteria	were	met:	age	≥20	years,	pa-
tients	with	 unresectable	 stage	 III/IV	 or	 recurrent	malignant	mela-
noma	 confirmed	by	 biopsy	 or	 cytology,	 previously	 untreated	with	
antineoplastic	 drugs	 (chemotherapy,	 molecular-targeted	 therapy	
or	 immunotherapy),	at	 least	1	measurable	 lesion	as	defined	by	the	
RECIST	guideline	version	1.1,	Eastern	Cooperative	Oncology	Group	
Performance	Status	 (ECOG-PS)	of	0-1,	 and	patients	 that	were	ex-
pected	to	survive	≥90	days.	In	the	case	of	preoperative	or	postop-
erative	 adjuvant	 therapy	 for	malignant	melanoma,	 patients	whose	
treatment	ended	≥6	weeks	prior	to	enrollment	and	in	whom	all	ad-
verse	drug	reactions	returned	to	baseline	or	stabilized	at	the	time	of	
enrollment	were	also	included.	Recurrence	was	defined	as	unresect-
able	recurrence.	The	stage	at	diagnosis	and	adherence	to	inclusion/
exclusion	criteria	regarding	local	recurrence	were	not	regulated,	and	
patients	were	included/excluded	at	the	discretion	of	the	attending	
physician;	thus,	it	is	possible	that	patients	exhibiting	local	recurrence	
were	included	in	the	study.
Patients	 were	 excluded	 if	 they	 had	 severe	 hypersensitivity	 to	
other	antibody	preparations,	residual	effects	of	prior	treatment	with	
radiation	therapy	or	surgical	 treatment,	an	autoimmune	disease	or	
a	history	of	recurrent	autoimmune	disease,	a	primary	tumor	in	the	
esophagus	or	rectum,	multiple	primary	cancers,	or	an	active	primary	
lesion	or	metastatic	lesion	in	the	brain	or	meninges.	Patients	also	had	
the	3-year	PFS	rate	was	17.2%.	A	long-term	response	was	observed	in	all	the	tumor	
types.	The	most	common	TRAE	included	skin	toxicity	(45.8%)	and	endocrine	disorders	
(29.2%).	This	study	demonstrated	the	long-term	efficacy	and	tolerability	of	nivolumab	
in	patients	with	advanced	or	recurrent	melanoma,	irrespective	of	melanoma	type.
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to	provide	a	 tumor	section	for	BRAF	V600	gene	mutation	analysis	
prior	to	enrollment	(Cobas	4800	BRAF	V600	Mutation	Test;	Roche	
Diagnostics).
2.3 | Ethics
The	institutional	review	board	at	each	site	approved	the	study	pro-
tocol,	 and	 this	 study	was	 carried	 out	 following	 the	 ethical	 princi-
ples	described	 in	 the	Declaration	of	Helsinki	and	the	 International	
Conference	on	Harmonization	Guideline	for	Good	Clinical	Practice.	
Written	informed	consent	was	provided	by	all	patients.	The	present	
study	was	registered	at	JapicCTI-142533.
2.4 | Efficacy endpoints
The	primary	 endpoint	was	 the	ORR,	which	was	 centrally	 assessed.	
The	 secondary	 endpoints,	 assessed	 in	 all	 study	patients	 and	 in	 the	
subpopulation	of	3-year	survivors,	included	OS,	progression-free	sur-
vival	 (PFS),	best	overall	 response	 (BOR),	disease	control	 rate	 (DCR),	
and	the	percent	change	in	the	sum	of	the	diameter	of	the	target	lesion.
A	 subgroup	 analysis	 was	 conducted	 to	 evaluate	 the	 ORR,	
DCR,	OS	 and	 PFS	when	 stratified	 by	 the	 presence	 of	 the	BRAF 
V600	mutation.	Considering	that	the	maximum	time	to	response	
was	5.7	months	 in	the	previous	analysis	of	this	study,	we	used	a	
post–hoc	landmark	analysis	of	OS	after	6	months	of	treatment	to	
evaluate	 the	 relationship	 between	 an	 early	 tumor	 response	 and	
subsequent	survival.	Post–hoc	subgroup	analyses	included	the	in-
vestigation	 of	ORR,	OS,	 and	 change	 in	 tumor	 diameter	 for	 each	
melanoma	 type	 (superficial	 spreading,	 acral	 lentiginous,	mucosal	
or	unknown).	 In	addition,	post–hoc	subgroup	analyses	were	per-
formed	 to	 investigate	ORR,	DCR,	OS	 and	PFS	 stratified	 by	 pro-
grammed	 death-ligand	 1	 (PD-L1)	 status	 (<1%	 or	 ≥1%),	 lactate	
dehydrogenase	 (LDH)	 levels	and	baseline	 tumor	diameter	 (based	
on	the	first	quartile	[≤21.950	mm]	and	third	quartile	[>64.615	mm]	
of	all	tumor	diameters	at	baseline).
2.5 | Safety endpoints
Safety	 variables	 that	 were	 assessed	 included	 treatment-related	 AE,	
which	were	graded	using	the	Common	Terminology	Criteria	for	Adverse	
Events	(version	4.0).	The	frequency	of	treatment-related	select	AE,	de-
fined	as	AE	with	potential	immunological	causes,	was	also	recorded.
2.6 | Statistical analysis
The	 target	 sample	 size	was	≥20	patients	with	 at	 least	14	patients	
characterized	as	having	a	BRAF	wild-type	malignant	melanoma	and	
at	 least	 6	 patients	 with	 a	 BRAF	 mutant	 malignant	 melanoma.2,8 
Sample	size	calculations	were	described	in	full	in	the	primary	phase	
II	study.2
Efficacy	 endpoints	 were	 analyzed	 using	 the	 full	 analysis	 set,	
and	 the	 proportion	 of	 patients	 and	 the	 2-sided	 90%	 confidence	
interval	 (CI)	were	 calculated	 for	ORR	and	DCR.	The	OS	and	PFS	
were	 reported	as	medians	 and	2-sided	90%	CI,	which	were	esti-
mated	using	the	Kaplan-Meier	method.	The	proportion	of	patients	
with	CR,	partial	response	(PR),	stable	disease	(SD)	and	PD,	as	well	
as	that	of	patients	who	were	not	evaluable,	were	calculated.	The	
2-sided	90%	CI	were	calculated	for	BOR	including	CR,	PR,	SD	and	
PD.	We	conducted	a	post–hoc	 landmark	analysis	 to	evaluate	 the	
difference	 in	 Kaplan-Meier	 estimates	 of	OS	 according	 to	 a	 BOR	
within	6	months.	Safety	endpoints	were	analyzed	using	the	safety	
analysis	set,	which	comprised	patients	who	had	received	the	study	
drug	at	least	once.
For	the	subgroup	analysis,	the	relationships	between	the	BRAF 
V600	mutation,	PD-L1	status	 (<1%	and	≥1%),	LDH	 levels,	baseline	
tumor	 diameter	 and	 efficacy	were	 analyzed	using	 the	 exploratory	
data	analysis	method.	Analysis	of	PD-L1	status	(<1%	and	≥1%),	LDH	
levels	and	baseline	tumor	diameter	were	post–hoc	subgroup	analy-
ses.	The	proportion	of	patients	and	2-sided	90%	CI	were	calculated	
for	ORR	 and	DCR.	 Statistical	 analyses	were	 performed	using	 SAS	
software	(version	9.4,	SAS	Institute).
3  | RESULTS
3.1 | Patient baseline characteristics and disposition
The	study	period	was	from	March	2014	to	September	2017,	and	the	
cut-off	date	was	15	September	2017.	Patient	baseline	characteristics	
are	described	in	Table	1.	Of	the	24	patients	included	in	the	primary	
phase	II	study,	1	patient	was	excluded	from	the	efficacy	analysis	be-
cause	 the	patient	was	 found	 to	have	multiple	 cancers	 after	 initia-
tion	of	the	study.2	In	total,	there	were	ten	3-year	survivors	included,	
among	whom	 tumor	 characteristics	 included	 superficial	 spreading	
(n	=	5),	acral	lentiginous	(n	=	2),	mucosal	(n	=	2),	and	unknown	(n	=	1).	
Patients	had	a	median	follow	up	of	32.9	months	(min,	max:	2.0,	39.6).
3.2 | Efficacy analysis
The	ORR	was	34.8%	(8/23	patients	[90%	CI:	20.8,	51.9])	with	CR	
and	PR	both	17.4%	each.	The	DCR	was	65.2%	(15/23	patients	[90%	
CI:	48.1,	79.2]).	The	BOR	assessed	in	ten	3-year	survivors	included	
CR	 in	 4	 patients,	 PR	 in	 1	 patient,	 SD	 in	 4	 patients,	 unknown	 in	
1	 patient,	 and	 no	PD	 reported	 (Table	 2).	 The	ORR	by	melanoma	
type	showed	that	superficial	spreading	tumor	type	(66.7%	[4/6	pa-
tients];	90%	CI:	34.7,	88.3)	was	associated	with	a	greater	response	
rate	compared	with	mucosal	 (33.3%	 [2/6	patients];	90%	CI:	11.7,	
65.3)	or	 acral	 lentiginous	 tumor	 type	 (28.6%	 [2/7	patients];	 90%	
CI:	 10.0,	 59.1).	 The	ORR	was	66.7%	 (2/3	patients;	 90%	CI:	 25.4,	
92.2)	 for	 stage	 IV	and	30.0%	 (6/20	patients;	90%	CI:	16.4,	48.4)	
for	recurrence.
The	median	OS	was	32.9	months,	and	the	OS	rate	after	1,	2	and	
3	years	was	69.6%	(90%	CI:	50.8,	82.3),	56.5%	(90%	CI:	38.0,	71.4)	
and	43.5%	(90%	CI:	26.4,	59.4),	respectively	(Figure	1A).	The	median	
PFS	was	5.9	months	(90%	CI:	2.8,	12.2),	and	the	PFS	rate	after	1,	2	
and	3	years	was	38.3%	 (90%	CI:	21.8,	54.6),	28.7%	 (90%	CI:	14.3,	
44.9)	and	17.2%	(90%	CI:	6.1,	33.1),	respectively	(Figure	1B).
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The	 3-year	 OS	 rates	 of	 acral	 lentiginous	 or	 mucosal	 melano-
mas	 (28.6%	 [90%	CI:	 6.4,	 56.5]	 and	33.3%	 [90%	CI:	 7.4,	 62.9],	 re-
spectively)	were	lower	compared	with	that	of	superficial	spreading	
melanoma	 (83.3%	 [90%	 CI:	 38.8,	 96.5])	 (Figure	 1C).	 A	 landmark	
analysis	of	OS	after	6	months	of	treatment	showed	that	the	OS	rate	
at	36	months	was	similar	between	patients	with	CR/PR	and	SD	at	
6	months	(Figure	1D),	suggesting	the	possibility	of	long-term	survival	
even	in	patients	with	SD.
In	 Figure	 2,	 the	waterfall	 plot	 highlights	 the	maximum	 change	
in	 target	 lesion	 size	 from	 baseline	 (%)	 by	 tumor	 type	 (superficial	
spreading,	 acral	 lentiginous	 and	 mucosal).	 All	 6	 patients	 with	 the	
superficial	spreading	type,	all	3	PD-L1	positive	(≥1%)	patients,	and	
5	out	of	6	patients	with	a	BRAF	mutation	showed	a	reduction	in	tar-
get	lesion	size	from	baseline.	A	spider	plot	of	the	percent	change	in	
target	lesion	diameter	from	baseline	(%)	by	tumor	type	is	shown	in	
Figure	3A	(mucosal	and	acral	lentiginous)	and	Figure	3B	(superficial	
spreading	and	unknown).	A	long-term	response	was	obtained	in	all	
the	tumor	types.
Table	3	shows	the	clinical	efficacy	(ORR,	DCR,	OS	and	PFS)	as	
stratified	by	the	presence	of	the	BRAF	V600	mutation,	the	PD-L1	
status,	normal	or	abnormal	serum	LDH	levels,	and	baseline	tumor	
diameter	 of	 another	 subgroup	 analysis.	 There	 was	 a	 clinical	 re-
sponse	 regardless	 of	 the	 presence	or	 absence	of	 the	BRAF V600 
mutation;	OS	rates	after	24	months	in	patients	with	BRAF	wild-type	
and BRAF	mutation	were	52.9%	and	66.7%,	 respectively,	 and	OS	
rates	after	36	months	were	41.2%	and	50.0%,	respectively	(Figure	
S1).	 In	addition,	PFS	rates	after	24	months	 in	patients	with	BRAF 
wild-type	and	BRAF	mutation	were	17.6%	and	62.5%,	respectively	
(Figure	S2).	The	PFS	rate	at	36	months	could	not	be	estimated	be-
cause	 none	 of	 the	 patients	were	 followed	 up	 for	 36	months.	 As	
for	PD-L1,	a	notable	effect	on	clinical	efficacy	was	observed	in	2	
TA B L E  1  Baseline	characteristics
Characteristics
All patients (n = 24)
n (%)
Sexa
Male 14	(58.3)
Female 10	(41.7)
Age	(y)a
Median 63.0
<65 13	(54.2)
≥65 11	(45.8)
ECOG-PSa
0 16	(66.7)
1 8	(33.3)
Stagea
IV 3	(12.5)
Recurrence 21	(87.5)
Typea
Acral	lentiginous 7	(29.2)
Mucosal 6	(25.0)
Superficial	spreading 6	(25.0)
Nodular 1	(4.2)
Lentigo	maligna 0	(0)
Unknown 4	(16.7)
History	of	surgerya
Yes 23	(95.8)
History	of	radiotherapya
Yes 3	(12.5)
History	of	adjuvant	therapya
0 9	(37.5)
1 7	(29.2)
≥2 8	(33.3)
BRAF	V600	statusa
Mutant 6	(25.0)
Wild-type 18	(75.0)
PD-L1	expression	status
≥1% 4	(16.7)
<1% 14	(58.3)
Could	not	be	determined	or	reported 6	(25.0)
LDH
≤ULN 17	(70.8)
>ULN 7	(29.2)
Tumor	diameter
≤21.950	mm 6	(25.0)
>21.950	mm	and	≤64.615	mm 12	(50.0)
>64.615	mm 6	(25.0)
ECOG-PS,	Eastern	Cooperative	Oncology	Group	Performance	Status;	
LDH,	lactate	dehydrogenase;	PD-L1,	programmed	death-ligand	1;	ULN,	
upper	limit	of	normal.
aData	from	Yamazaki	et	al,	Cancer	Sci	2017;	108:	1223-30.	
TA B L E  2  Response	rate
Response
All patients (n = 23b)
3‐y 
survivors 
(n = 10)
n % 90% CI n
BOR
CR 4 17.4 8.1-33.6 4
PR 4 17.4 8.1-33.6 1
SDa 7 30.4 17.4-47.6 4
PDa 7 30.4 17.4-47.6 0
Unknownc 1 4.3 1
ORR	(CR	+	PR) 8 34.8 20.8-51.9 5
DCR	
(CR	+	PR	+	SD)
15 65.2 48.1-79.2 9
BOR,	best	overall	response;	CI,	confidence	interval;	CR,	complete	
response;	DCR	disease	control	rate;	ORR,	overall	response	rate;	PD,	
progressive	disease;	PR,	partial	response;	SD,	stable	disease.
aData	from	Yamazaki	et	al,	Cancer	Sci	2017;	108:	1223-30.	
bOne	patient	who	was	found	after	study	completion	to	have	multiple	
cancers	from	the	start	was	excluded	from	the	efficacy	analysis	set.	
cNo	target	lesions	were	identified	at	baseline.	
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out	of	3	patients	who	had	a	PD-L1	positive	(≥1%)	status.	The	me-
dian	OS	was	not	reached	during	the	study	period,	whereas	a	PFS	of	
26.2	months	was	associated	with	a	PD-L1	positive	status	(Table	3).	
In	comparison,	a	PD-L1	status	of	<1%	was	associated	with	a	me-
dian	OS	of	14.0	months	and	a	median	PFS	of	3.5	months.	Similarly,	
serum	 LDH	 levels	 also	 greatly	 affected	 the	median	OS	 and	 PFS.	
A	serum	LDH	≤	the	upper	limit	of	normal	(ULN)	resulted	in	a	me-
dian	OS	 that	was	 not	 reached	 and	 a	median	 PFS	 of	 7.9	months.	
In	 contrast,	 a	 serum	LDH	>	 the	ULN	 resulted	 in	 a	median	OS	of	
11.7	months	and	a	median	PFS	of	1.4	months	(Table	3).	In	addition,	
OS	and	PFS	were	also	found	to	be	associated	with	tumor	diameter	
at	baseline.	In	patients	with	smaller	tumors	(≤21.950	mm),	the	me-
dian	OS	was	not	reached	during	the	study	period,	while	the	median	
PFS	was	26.6	months,	compared	with	11.8	months	and	2.8	months,	
respectively,	in	patients	with	larger	tumors	(>64.615	mm).
3.3 | Safety analysis
Treatment-related	AE	were	observed	in	100.0%	(10/10	patients)	of	
3-year	survivors	and	in	83.3%	(20/24	patients)	of	the	total	patient	
group.	 In	 the	 total	patient	group,	 the	most	common	 treatment-re-
lated	 AE	 that	 were	 observed	 in	 ≥10%	 of	 patients	 are	 shown	 in	
Table	4.	Four	grade	3-4	treatment-related	AE	(anemia,	fever,	colitis	
and	renal	impairment)	were	reported	in	3	patients.
There	were	only	2	incidences	of	treatment-related	AE	leading	to	
discontinuation	in	all	patients	(n	=	1	for	colitis	and	pleural	diffusion)	
(Table	5).	The	most	common	treatment-related	select	AE	were	skin	
toxicity	(n	=	11,	45.8%),	endocrine	disorders	(n	=	7,	29.2%),	gastroin-
testinal	toxicity	(n	=	2,	8.3%),	hepatotoxicity	(n	=	2,	8.3%)	and	pulmo-
nary	toxicity	(n	=	1,	4.2%)	(Table	6).	There	were	no	treatment-related	
deaths.
4  | DISCUSSION
The	present	study	demonstrated	the	long-term	efficacy	and	safety	of	
nivolumab	in	Japanese	patients	with	advanced	or	recurrent	melanoma.	
The	 median	 OS	 reported	 here	 was	 similar	 to	 that	 of	 patients	 who	
received	nivolumab	monotherapy	 in	 the	CheckMate	067	study	 (32.9	
and	 37.6	 months,	 respectively).9	 There	 were	 long-term	 survivors	
even	among	patients	with	SD.	This	phenomenon	may	occur	due	to	an	
equilibrium	being	achieved	between	tumor	growth	and	tumor	shrinkage	
by	therapy,	or	the	tumor	may	have	lost	its	proliferative	activity	despite	
being	observed	during	computed	tomography	scan	imaging.10
In	 this	 study,	 patient	 characteristics	 were	 generally	 consis-
tent	 with	 those	 who	 received	 nivolumab	 monotherapy	 in	 the	
CheckMate	067	study.9	However,	 the	percentage	of	tumor	types	
reported	in	Japan11	for	acral	lentiginous	(46%),	superficial	spreading	
F I G U R E  1  Kaplan–Meier	curves	for	(A)	OS,	(B)	PFS,	(C)	OS	by	melanoma	type	and	(D)	OS	by	response	(landmark	analysis).	One	patient	
found	to	have	multiple	cancers	after	initiation	of	the	trial	was	excluded	from	the	group	to	be	analyzed	for	effectiveness.	CI,	confidence	
interval;	CR,	complete	response;	NR,	not	reached;	OS,	overall	survival;	PD,	progressive	disease;	PFS,	progression-free	survival;	PR,	partial	
response;	SD,	stable	disease 
[Correction	added	on	05	June	2019,	after	first	online	publication:	Figure	1C	was	replaced	to	include	mucosal	data.]
(A) (B)
(C) (D)
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(23%)	 and	mucosal	 (10%)	 is	 different	 to	what	 has	 been	 reported	
in	 other	 countries	 (5%,	 54%	 and	 .4%	 respectively).12	 It	 has	 been	
reported	 that	acral	 lentiginous	 (50%-58%)13	 and	mucosal	 (15%)14 
melanoma	are	common	subtypes	in	Asian	countries.	Thus,	the	per-
centage	of	 tumors	 that	are	acral	 lentiginous	or	mucosal	 is	higher	
in	East	Asian	 countries,	 including	 Japan,	 than	 in	other	 countries.	
In	 the	present	study,	 the	distribution	of	acral	 lentiginous	 (29.2%)	
and	mucosal	 (25.0%)	 types	 accounted	 for	 over	 half	 of	 the	 study	
population	and	when	investigating	the	3-year	OS	rate,	nivolumab	
was	not	as	effective	in	patients	with	mucosal	or	acral	 lentiginous	
types	compared	with	patients	with	the	superficial	spreading	type.	
Similar	 results	 have	 been	 reported	 previously.15	 This	 difference	
in	tumor	response	by	melanoma	type	may	be	the	reason	why	the	
ORR	and	3-year	OS	rate	in	this	study	was	lower	than	what	was	re-
ported	in	the	CheckMate	067	study.9	To	explain	these	differences	
in	response	rates,	the	tumor	mutation	burden	(TMB)	may	be	less	in	
acral	lentiginous	and	mucosal	types	compared	with	the	superficial	
spreading	type.16
In	 cancer	 cells	 with	 a	 high	 TMB	 level,	 the	 immune	 system	 is	
thought	to	more	easily	recognize	the	tumor	due	to	 increased	neo-
antigen	levels.	Here,	an	interferon	gamma	messenger	RNA	signature	
has	been	previously	reported	to	correlate	with	higher	TMB	levels	in	
tumor	biopsies,	which	results	in	greater	T-cell	activation.17 In addi-
tion,	it	was	also	reported	that	the	OS	was	better	in	patients	with	a	
high	TMB	when	nivolumab	was	administered	in	the	ipilimumab-naïve	
group	in	the	CheckMate	038	study.18	According	to	an	interim	anal-
ysis	of	a	Japanese	post–marketing	surveillance	study,	there	was	no	
difference	in	OS	between	cutaneous	and	mucosal	melanoma	types,	
although	the	cutaneous	type	does	include	acral	 lentiginous,	super-
ficial	spreading	and	nodular	types.19	Therefore,	further	research	 is	
required	 to	 fully	 elucidate	 the	 efficacy	 of	 nivolumab	 treatment	 in	
different	melanoma	types.
In	this	study,	only	3	patients	(superficial	spreading	[n	=	2]	and	
acral	lentiginous	[n	=	1])	were	confirmed	to	be	positive	for	PD-L1.	
None	 of	 the	 patients	 with	 mucosal	 melanomas	 were	 confirmed	
to	 be	 PD-L1	 positive,	 which	 is	 consistent	with	 previous	 reports	
that	 have	 shown	 there	were	 fewer	PD-L1-positive	patients	with	
the	mucosal	type	than	the	cutaneous	type.20,21	The	ORR	was	rel-
atively	higher	in	PD-L1-positive	patients	versus	those	with	PD-L1	
<1%.	However,	this	result	is	limited	by	the	small	number	of	PD-L1	
positive	patients	(n	=	3).
F I G U R E  2  Maximum	change	in	target	
lesion	size	from	baseline	(%)	by	tumor	
type	(in	the	presence	or	absence	of	PD-
L1	expression	or	BRAF	mutation).	One	
patient	found	to	have	multiple	cancers	
after	initiation	of	the	trial	was	excluded	
from	the	group	to	be	analyzed	for	
effectiveness.	PD-L1,	programmed	death	
1	ligand
F I G U R E  3  Percent	change	in	target	tumor	diameter	over	time	
in	(A)	acral	lentiginous	and	mucosal	tumor	types	and	(B)	superficial	
spreading	and	unknown	tumor	types
(A)
(B)
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The	percentage	of	patients	with	a	BRAF	mutation	in	this	study	
was	25%,	which	was	similar	to	that	reported	in	2	previous	Japanese	
studies.22,23	The	incidence	of	BRAF	mutations	is	lower	in	Japanese	
patients	than	in	Caucasian	patients,	although	in	the	CheckMate	067	
study,	efficacy	was	confirmed	regardless	of	BRAF	 status.9	We	re-
port	that	nivolumab	was	effective	in	both	BRAF	wild-type	and	BRAF 
mutant	melanomas	based	on	our	reported	median	OS	and	PFS.
The	 observation	 period	 in	 this	 report	was	 14.1	months	 longer	
than	in	our	previous	report	(18.8	months	vs	32.9	months),	but	there	
were	no	additional	AE	of	clinical	concern	observed	over	time.2	This	
confirms	the	long-term	safety	of	nivolumab	treatment.
This	study	had	limitations,	which	included	the	open-label	design,	
the	small	sample	size	and	the	absence	of	a	control	group.
In	 conclusion,	 we	 report	 the	 long-term	 survival	 data	 for	
nivolumab	monotherapy	in	previously	untreated	Japanese	patients	
with	advanced	or	recurrent	malignant	melanoma.	We	also	show	that	
long-term	survival	can	be	expected,	even	 in	patients	with	SD,	and	
that	efficacy	was	observed,	irrespective	of	melanoma	type,	includ-
ing	acral	lentiginous	and	mucosal	types,	which	are	more	prevalent	in	
Japanese	patients.	The	long-term	safety	of	nivolumab	therapy	was	
demonstrated	and	these	results	were	consistent	with	other	safety	
data	reported	to	date.
TA B L E  3  Subgroup	analysis	of	clinical	efficacy
All patients (n)
ORR DCR OS PFS
n (%) [90% CI] n (%) [90% CI] Median (mo) Median (mo)
BRAF
Wild-type 17 4	(23.5)	[11.0,	43.3] 10	(58.8)	[39.3,	75.9] 26.9 4.2
Mutant 6 4	(66.7)	[34.7,	88.3] 5	(83.3)	[49.8,	96.2] NR 26.2
PD-L1a
≥1% 3 2	(66.7)	[25.4,	92.2] 3	(100.0)	[52.6,	100.0] NR 26.2
<1% 14 4	(28.6)	[13.5,	50.6] 8	(57.1)	[36.0,	75.9] 14.0 3.5
LDH
≤ULN 16 6	(37.5)	[20.8,	57.8] 12	(75.0)	[54.5,	88.2] NR 7.9
>ULN 7 2	(28.6)	[10.0,	59.1] 3	(42.9)	[18.6,	71.1] 11.7 1.4
Tumor	diameter	at	baseline	(mm)
≤21.950b 5 3	(60.0)	[27.2,	85.7] 4	(80.0)	[43.5,	95.4] NR 26.6
>21.950b	and	≤64.615c 12 3	(25.0)	[10.5,	48.7] 8	(66.7)	[43.1,	84.1] 29.9 4.9
>64.615c 6 2	(33.3)	[11.7,	65.3] 3	(50.0)	[22.1,	77.9] 11.8 2.8
CI,	confidence	interval;	DCR	disease	control	rate;	LDH,	lactate	dehydrogenase;	NR,	not	reached;	PD-L1,	programmed	death-ligand	1;	PFS,	progres-
sion-free	survival;	ORR,	overall	response	rate;	OS,	overall	survival;	ULN,	upper	limit	of	normal.
aCould	not	be	determined	or	reported	(n	=	6).	
bFirst	quartile.	
cThird	quartile.	
 Preferred term
All patients (n = 24) 3‐y survivors (n = 10)
All grades, n (%)
Grade 3‐4 
n (%)
All grades 
n (%)
Grade 3‐4 
n (%)
Overall 20	(83.3) 3	(12.5) 10	(100.0) 0
Vitiligo 9	(37.5) 0 7	(70.0) 0
Hypothyroidism 6	(25.0) 0 2	(20.0) 0
Malaise 6	(25.0) 0 4	(40.0) 0
Pruritus 6	(25.0) 0 3	(30.0) 0
Nausea 3	(12.5) 0 1	(10.0) 0
Weight	decreased 3	(12.5) 0 1	(10.0) 0
Appetite	decreased 3	(12.5) 0 1	(10.0) 0
Arthralgia 3	(12.5) 0 2	(20.0) 0
Rash	maculo-papular 3	(12.5) 0 2	(20.0) 0
TA B L E  4   Incidence	of	treatment-
related	adverse	events	observed	in	≥10%	
of	overall	patients	(median	follow	up:	
32.9	mo)
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